Dimensional Fund Advisors LP Purchases 12,285 Shares of Merit Medical Systems, Inc. $MMSI

Dimensional Fund Advisors LP boosted its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 1.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,237,298 shares of the medical instruments supplier’s stock after acquiring an additional 12,285 shares during the period. Dimensional Fund Advisors LP’s holdings in Merit Medical Systems were worth $85,287,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Los Angeles Capital Management LLC acquired a new position in shares of Merit Medical Systems during the fourth quarter worth $25,000. Maseco LLP acquired a new stake in shares of Merit Medical Systems in the 4th quarter worth $26,000. Torren Management LLC purchased a new position in Merit Medical Systems during the 4th quarter worth $38,000. Covestor Ltd grew its stake in Merit Medical Systems by 252.6% during the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 336 shares during the last quarter. Finally, Danske Bank A S acquired a new position in Merit Medical Systems during the 3rd quarter valued at about $42,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

More Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates. Merit reported non-GAAP EPS of $1.19, up from $1.01 a year earlier and well above the $0.96 consensus estimate. Revenue rose 9.5% year over year to $418.8 million, exceeding expectations of $405.3 million. Merit Medical Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved. GAAP operating margin expanded to 14.4% from 12.3%, while non-GAAP operating margin increased to 22.6% from 21.2%. GAAP EPS rose 20%, and non-GAAP EPS increased 18% year over year. Merit Medical Reports Second Quarter 2026 Results
• Positive Sentiment: Full-year EPS guidance was raised or reaffirmed above consensus. Merit provided 2026 adjusted EPS guidance of $4.25 to $4.35, compared with the analyst consensus of $3.98. Revenue guidance of approximately $1.6 billion was in line with expectations, indicating that earnings growth and margin execution are key drivers of the outlook. Merit Medical Raises 2026 Outlook
• Neutral Sentiment: The earnings call transcript and additional metric analysis may provide more detail on product demand, regional performance, and management’s expectations, but the headline release did not indicate a material change to the revenue outlook. MMSI Q2 2026 Earnings Call Transcript
• Negative Sentiment: Cash generation weakened year to date. Operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million. Investors may monitor whether this reflects temporary working-capital needs or a more persistent pressure on cash conversion. Merit Medical Q2 Financial Highlights

Merit Medical Systems Stock Up 3.1%

MMSI stock opened at $83.35 on Friday. The company has a market capitalization of $4.97 billion, a P/E ratio of 36.08, a price-to-earnings-growth ratio of 2.51 and a beta of 0.52. Merit Medical Systems, Inc. has a 12 month low of $59.74 and a 12 month high of $94.75. The firm’s fifty day simple moving average is $69.45 and its 200-day simple moving average is $71.69. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, equities research analysts forecast that Merit Medical Systems, Inc. will post 3.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on MMSI. Wells Fargo & Company decreased their price target on Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Citigroup restated an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Wall Street Zen downgraded shares of Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Weiss Ratings lowered shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $91.78.

Insider Activity

In related news, insider Brian G. Lloyd purchased 2,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were bought at an average cost of $62.62 per share, with a total value of $125,240.00. Following the transaction, the insider owned 2,000 shares of the company’s stock, valued at approximately $125,240. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.70% of the stock is currently owned by company insiders.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.